PortalPublikationenDurability of SVR in chronic hepatitis C patients treated wi...

Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral

Standard

Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral. / Rutter, K; Hofer, H; Beinhardt, S; Dulic, M; Gschwantler, M; Maieron, A; Laferl, H; Stättermayer, A F; Scherzer, T-M; Strassl, R; Holzmann, H; Steindl-Munda, P; Ferenci, P.

in: ALIMENT PHARM THER, Jahrgang 38, Nr. 2, 01.07.2013, S. 118-23.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Rutter, K, Hofer, H, Beinhardt, S, Dulic, M, Gschwantler, M, Maieron, A, Laferl, H, Stättermayer, AF, Scherzer, T-M, Strassl, R, Holzmann, H, Steindl-Munda, P & Ferenci, P 2013, 'Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral', ALIMENT PHARM THER, Jg. 38, Nr. 2, S. 118-23. https://doi.org/10.1111/apt.12350

APA

Rutter, K., Hofer, H., Beinhardt, S., Dulic, M., Gschwantler, M., Maieron, A., Laferl, H., Stättermayer, A. F., Scherzer, T-M., Strassl, R., Holzmann, H., Steindl-Munda, P., & Ferenci, P. (2013). Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral. ALIMENT PHARM THER, 38(2), 118-23. https://doi.org/10.1111/apt.12350

Vancouver

Rutter K, Hofer H, Beinhardt S, Dulic M, Gschwantler M, Maieron A et al. Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral. ALIMENT PHARM THER. 2013 Jul 1;38(2):118-23. https://doi.org/10.1111/apt.12350

Bibtex

@article{402fd36802534d739dbbab4f7f62a77e,
title = "Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral",
abstract = "BACKGROUND: The introduction of direct-acting anti-virals has increased sustained virological response (SVR) rates in chronic hepatitis C genotype 1 infection. At present, data on long-term durability of viral eradication after successful triple therapy are lacking.AIM: To evaluate the long-term durability of viral eradication in patients treated with triple therapy, including direct-acting anti-virals.METHODS: Patients who participated in randomised, controlled trials or an extended access programme of treatment with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral (telaprevir, danoprevir, faldaprevir, simeprevir, mericitabine, balapiravir) were followed after achieving SVR. The median follow-up after the patients was 21 (range: 7-64) months.RESULTS: One hundred and three patients with chronic hepatitis C genotype 1 infection [f/m: 34/69; GT-1b: 67 GT-1a: 34, GT-4: 2; mean age: 47.6 years (45.5-49.7; 95% CI)] achieving a SVR triple therapy were followed. Two cases of late relapses (2/103, 1.9%; 95% CI: 0.24-6.8) were observed. One patient was cirrhotic, both carried the genotype 1b and completed the prescribed treatment. The relapses occurred 8 and 12 months after cessation of anti-viral treatment. Cloning sequencing revealed identical sequence in both patients. Resistance analysis revealed no presence of viral resistance.CONCLUSION: Like the SVR after peginterferon-α2/ribavirin combination treatment, HCV eradication after triple therapy remains durable after long-term follow-up.",
keywords = "Antiviral Agents, Drug Therapy, Combination, Female, Follow-Up Studies, Hepacivirus, Hepatitis C, Chronic, Humans, Interferon-alpha, Male, Middle Aged, Polyethylene Glycols, Randomized Controlled Trials as Topic, Recombinant Proteins, Ribavirin, Time Factors, Treatment Outcome, Viral Load",
author = "K Rutter and H Hofer and S Beinhardt and M Dulic and M Gschwantler and A Maieron and H Laferl and St{\"a}ttermayer, {A F} and T-M Scherzer and R Strassl and H Holzmann and P Steindl-Munda and P Ferenci",
note = "{\textcopyright} 2013 John Wiley & Sons Ltd.",
year = "2013",
month = jul,
day = "1",
doi = "10.1111/apt.12350",
language = "English",
volume = "38",
pages = "118--23",
journal = "ALIMENT PHARM THER",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral

AU - Rutter, K

AU - Hofer, H

AU - Beinhardt, S

AU - Dulic, M

AU - Gschwantler, M

AU - Maieron, A

AU - Laferl, H

AU - Stättermayer, A F

AU - Scherzer, T-M

AU - Strassl, R

AU - Holzmann, H

AU - Steindl-Munda, P

AU - Ferenci, P

N1 - © 2013 John Wiley & Sons Ltd.

PY - 2013/7/1

Y1 - 2013/7/1

N2 - BACKGROUND: The introduction of direct-acting anti-virals has increased sustained virological response (SVR) rates in chronic hepatitis C genotype 1 infection. At present, data on long-term durability of viral eradication after successful triple therapy are lacking.AIM: To evaluate the long-term durability of viral eradication in patients treated with triple therapy, including direct-acting anti-virals.METHODS: Patients who participated in randomised, controlled trials or an extended access programme of treatment with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral (telaprevir, danoprevir, faldaprevir, simeprevir, mericitabine, balapiravir) were followed after achieving SVR. The median follow-up after the patients was 21 (range: 7-64) months.RESULTS: One hundred and three patients with chronic hepatitis C genotype 1 infection [f/m: 34/69; GT-1b: 67 GT-1a: 34, GT-4: 2; mean age: 47.6 years (45.5-49.7; 95% CI)] achieving a SVR triple therapy were followed. Two cases of late relapses (2/103, 1.9%; 95% CI: 0.24-6.8) were observed. One patient was cirrhotic, both carried the genotype 1b and completed the prescribed treatment. The relapses occurred 8 and 12 months after cessation of anti-viral treatment. Cloning sequencing revealed identical sequence in both patients. Resistance analysis revealed no presence of viral resistance.CONCLUSION: Like the SVR after peginterferon-α2/ribavirin combination treatment, HCV eradication after triple therapy remains durable after long-term follow-up.

AB - BACKGROUND: The introduction of direct-acting anti-virals has increased sustained virological response (SVR) rates in chronic hepatitis C genotype 1 infection. At present, data on long-term durability of viral eradication after successful triple therapy are lacking.AIM: To evaluate the long-term durability of viral eradication in patients treated with triple therapy, including direct-acting anti-virals.METHODS: Patients who participated in randomised, controlled trials or an extended access programme of treatment with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral (telaprevir, danoprevir, faldaprevir, simeprevir, mericitabine, balapiravir) were followed after achieving SVR. The median follow-up after the patients was 21 (range: 7-64) months.RESULTS: One hundred and three patients with chronic hepatitis C genotype 1 infection [f/m: 34/69; GT-1b: 67 GT-1a: 34, GT-4: 2; mean age: 47.6 years (45.5-49.7; 95% CI)] achieving a SVR triple therapy were followed. Two cases of late relapses (2/103, 1.9%; 95% CI: 0.24-6.8) were observed. One patient was cirrhotic, both carried the genotype 1b and completed the prescribed treatment. The relapses occurred 8 and 12 months after cessation of anti-viral treatment. Cloning sequencing revealed identical sequence in both patients. Resistance analysis revealed no presence of viral resistance.CONCLUSION: Like the SVR after peginterferon-α2/ribavirin combination treatment, HCV eradication after triple therapy remains durable after long-term follow-up.

KW - Antiviral Agents

KW - Drug Therapy, Combination

KW - Female

KW - Follow-Up Studies

KW - Hepacivirus

KW - Hepatitis C, Chronic

KW - Humans

KW - Interferon-alpha

KW - Male

KW - Middle Aged

KW - Polyethylene Glycols

KW - Randomized Controlled Trials as Topic

KW - Recombinant Proteins

KW - Ribavirin

KW - Time Factors

KW - Treatment Outcome

KW - Viral Load

U2 - 10.1111/apt.12350

DO - 10.1111/apt.12350

M3 - SCORING: Journal article

C2 - 23710895

VL - 38

SP - 118

EP - 123

JO - ALIMENT PHARM THER

JF - ALIMENT PHARM THER

SN - 0269-2813

IS - 2

ER -